News & Publications

MiRXES Is Expanding the Technical Team for Research Scientists and Research Officers

MiRXES is expanding its technical team for positions of research scientists and research officers. Successful candiates will be working in a highly motivated team and innovative working environment. We offer excellent development opportunities in a globally oriented company and a competitive salary and bonus package.

Hiring Now

Positions Open at MiRXES for DX Development & Quality Assurance

Hiring Now
Blog Image

MiRXES founders won Scientist-Entrepreneur Award from A*Star

MiRXES founders are awarded as inspiring Scientist-Entrepreneurs by A*Star. Prof. Too Heng Phon, Dr.Zhou Lihan and Dr.Zou Ruiyang started the company from a university lab; and strived to grow the innovative technology with the support from A*Star. The award recognizes MiRXES' effort of bringing the technology to the market and translating innovative solutions from bench to bedside.

MiRXES won 1st runner up in BioSingapore Innovative Biomedical Company

MiRXES focuses on proprietary ultra-sensitive quantitative technology to detect microRNA cancer biomarkers. Currently, MiRXES is running the world's largest prospective clinical studies for early stage gastric, lung and breast cancer diagnostics utilizing the miRNA biomarkers. This award recognises companies that are on the forefront of innovation across the Singapore Biosciences Industry and celebrates the spirit of innovation and creative business solutions in the highly competitive biomedical and medical technology industry.

Read More
Blog Image

MiRXES Holds Talks in BIO Europe Spring

MiRXES networking and meeting with Pharma, MedTech and CRO customers and collaborators at BIO Europe Spring in Barcelona.
If you missed meeting us there, be sure to meet us at BIO in San Diego and The Liquid Biopsy Summit in San Francisco this June.

Blog Image

MiRXES Won Most Promising Start Up in OCBC Emerging Enterprice Awards (EE2016)

MiRXES' efforts to revolutionize cancer detection was recognized at the 2016 Emerging Enterprise Awards (EE 2016) in Singapore. Professor Too Heng-Phon accepted the Most Promising Startup trophy from Dr Koh Poh Koon, Minister of State for National Development and Trade and Industry, at a gala dinner held at St Regis Hotel on 16 Sep 2016.
The annual award is organised by The Business Times and OCBC Bank to celebrate entrepreneurial businesses in Singapore.

Read More

Johnson and Johnson Announces Collaboration with MiRXES on Gestational Diabetes

GDM is diagnosed when carbohydrate intolerance (hyperglycemia) is developed or recognized during pregnancy for the first time. Consequences for mother and child can be severe and include increased risks of birth trauma, jaundice, respiratory distress syndrome, macrosomia, cesarean section, and maternal hypertensive disorder. Longer term, 30-50 percent of women with GDM develop type 2 diabetes (T2D) and children have an increased risk of obesity and T2D, as well as asthma and behavioral disorders. Using biomarkers to segment the population at high risk, the GDM Venture team is focused on developing disease interception solutions that address the root causes of GDM.

Read More

MiRXES Gastric Cancer Kit Featured in Singapore’s National News

A blood test to assess early-stage stomach cancer, a major killer here, could be rolled out in local hospitals as soon as next year. Instead of going for an uncomfortable endoscopy to see if they are at risk, patients can first take the blood test to see whether more detailed tests are needed.

The diagnostic kit is the brainchild of MiRXES - a spin-off by researchers from the Agency for Science, Technology and Research (A*Star). With just a few drops of blood, doctors are able to detect accurately whether a patient has developed early-stage gastric cancer.

Read More

MiRXES launches Epstein-Barr Virus (EBV) microRNA Assays (BART miRNAs)

Read More